iTeos Therapeutics (NASDAQ:ITOS – Get Rating) had its target price reduced by JPMorgan Chase & Co. from $34.00 to $32.00 in a research note released on Thursday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.
Separately, Wedbush cut their price target on shares of iTeos Therapeutics from $45.00 to $33.00 and set an outperform rating for the company in a report on Thursday.
iTeos Therapeutics Stock Down 4.4 %
Shares of ITOS stock opened at $14.12 on Thursday. iTeos Therapeutics has a 12-month low of $13.81 and a 12-month high of $37.26. The company has a market capitalization of $504.37 million, a P/E ratio of 5.49 and a beta of 1.42. The firm has a 50-day moving average price of $18.81 and a 200 day moving average price of $19.40.
Hedge Funds Weigh In On iTeos Therapeutics
iTeos Therapeutics Company Profile
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
- Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.